Disclaimer

The information contained in the website is solely intended for professional investors. Some funds shown on this website fall outside the scope of the Dutch Act on the Financial Supervision (Wet op het financieel toezicht) and therefore do not (need to) have a license from the Authority for the Financial Markets (AFM).

The funds shown on this website may not be available in your country. Please select your country website (top right corner) to view the products that are available in your country.

Neither information nor any opinion expressed on the website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports, which can be all be obtained free of charge at this website and at the Robeco offices in each country where Robeco has a presence.

Please confirm that you are a professional investor and/or institutional investor and that you have read, understood and accept the terms of use for this website..

I Disagree
Hope for our health

Hope for our health

27-06-2014 | Research

The development of new cures for severe diseases and the aging of the population have blown up healthcare costs. Fortunately, new tools and technologies promise to enhance productivity and improve healthcare quality. Henk Grootveld, Portfolio Manager of Rolinco and Robeco Global Growth Trends Equities, and Steef Bergakker, Robeco’s Trend Analyst, discuss these exciting new developments and the arising investment opportunities.

  • Henk Grootveld
    Henk
    Grootveld
    Fund Manager Rolinco & Head of Trends Investing

Modern medicine has been very successful in treating once fatal diseases. Infant diseases have almost been erased thanks to pediatric vaccines. Once lethal diseases like tuberculosis, diphtheria and cholera have been tamed and even hard-to-crack HIV has been transformed from a fatal disease into a chronic one. There is also hope of further successes in the future. In cancer, for example, a new breakthrough therapy has been discovered that looks to be defeating at least some of the many different types of cancer.

Discover the latest insights
Subscribe

Explosion of healthcare costs

Unfortunately, this success has had an unwelcome side-effect: an explosion of healthcare costs. The combination of more diseases that can be treated and more people that have access to healthcare has caused healthcare costs to outgrow GDP for decades. In many developed nations healthcare spending already exceeds 10% of GDP and is still climbing. 

The demand for healthcare is virtually guaranteed to soar over the coming decades, simply because healthcare demand is positively correlated to age and the proportion of elderly people is inexorably growing in virtually every region of the world. If we cannot find ways to dramatically increase healthcare productivity, costs will run out of control sooner rather than later and healthcare will become unaffordable.

New ways to raise productivity

Fortunately, exciting new tools and technologies that promise huge productivity improvements in healthcare are now rapidly evolving and gaining critical mass. Examples are DNA testing, diagnostic imaging technology, artificial intelligence and personalized medicine. For investors, there are three trends from which we can benefit, i.e. fragmentation, customization and decentralization.

Subjects related to this article are: